# Taisho Pharmaceutical Holdings

> Taisho Pharmaceutical Holdings is a VC fund backing Health Care. See 12 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Tokyo, Japan
- Total investments: 12
- Last investment: Mar 2025
- Lead investor: 8%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/taisho-pharmaceutical/
- Website: https://www.taisho-holdings.co.jp/en/
- Facebook: https://www.facebook.com/profile.php?id=416322941758898&paipv=0&eav=AfakphtlvfiIqsdC2GAXD_i2w7tLw2Ia0aoNAGUziZuEhG45FAq8MhJbrOmVOGW8CBI&_rdr

Taisho Pharmaceutical Holdings is a producer of generic drugs. They mainly manufacture and sell general cold medicines, allergy drugs, lipovitan series, pabron series, tempra, and more.

## Contacts

5 contacts available for Taisho Pharmaceutical Holdings. Shizune tracks 1 team members at Taisho Pharmaceutical Holdings. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/taisho-pharmaceutical-holdings?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $2.1M–$12M |
| Series C | $2.3M–$100M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 6 | 50% |
| Biotechnology | 3 | 25% |
| Medical | 2 | 17% |
| Wearables | 2 | 17% |
| Manufacturing | 2 | 17% |

22 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 5 | 42% |
| Series C | 2 | 17% |
| Seed | 1 | 8% |
| Series B | 1 | 8% |
| Series D | 1 | 8% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Japan | 6 | 50% |
| United States | 2 | 17% |
| Israel | 1 | 8% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Akira Uehara | Chairman, President, and CEO | 0 | https://shizune.co/investors/profile/akira-uehara |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Biolinq | Biolinq is a digital health platform developer that aims to create a pipeline of biomonitoring solutions. The company's platform includes a skin-applied, minimally invasive electrochemical biosensor that analyzes biomarkers in the interstitial fluid to provide actionable health information while continuously monitoring multiple biomarkers,allowing diabetic patients to monitor their blood glucose levels. | $100M | Series C | Mar 19, 2025 |  |
| Biolinq | Biolinq is a digital health platform developer that aims to create a pipeline of biomonitoring solutions. The company's platform includes a skin-applied, minimally invasive electrochemical biosensor that analyzes biomarkers in the interstitial fluid to provide actionable health information while continuously monitoring multiple biomarkers,allowing diabetic patients to monitor their blood glucose levels. | $58M | Venture - Series Unknown | Apr 04, 2024 |  |
| Biolinq | Biolinq is a digital health platform developer that aims to create a pipeline of biomonitoring solutions. The company's platform includes a skin-applied, minimally invasive electrochemical biosensor that analyzes biomarkers in the interstitial fluid to provide actionable health information while continuously monitoring multiple biomarkers,allowing diabetic patients to monitor their blood glucose levels. | $58M | Series D | Apr 04, 2024 |  |
| VIE STYLE | VIE STYLE offers wearable music device and AI technology services. | $2.1M | Series A | Mar 07, 2024 |  |
| Linqmed | Linqmed is a pharmaceutical company that specializes in the research and development of radiopharmaceuticals for cancer treatment. | $4.8M | Series A | Dec 22, 2023 |  |
| AuB | AuB is an intestinal microflora analysis that contributes to the athlete's performance improvement and human health maintenance. | $2.3M | Series C | Jun 01, 2022 |  |
| Biolinq | Biolinq is a digital health platform developer that aims to create a pipeline of biomonitoring solutions. The company's platform includes a skin-applied, minimally invasive electrochemical biosensor that analyzes biomarkers in the interstitial fluid to provide actionable health information while continuously monitoring multiple biomarkers,allowing diabetic patients to monitor their blood glucose levels. | $100M | Series B | Nov 02, 2021 |  |
| Moodify | Moodify transforms the way scents are made to make better, more effective and sustainable consumer products, making the design and manufacturing faster, more scalable, accurate, cost effective and compliant. This, by harnessing 15 years of neuroscience research by the Weizmann Institute, together with cutting edge bioinformatics machine learningtechnologies. | $8M | Series A | Aug 19, 2021 |  |
| Edifice Health | Edifice Health is a spin-out company from a 10-year research study on immune profiling from Stanford University, the Stanford 1,000 Immunomes Project. The technology is the first biomarker composite scoring system to measure immune health and the Inflammatory Age® of an individual which predicts the onset of multiple chronic diseases and providescomprehensive health insights designed to help people change the course of their aging process. | $12M | Series A | Apr 22, 2021 |  |
| Aiwell | Aiwell is a medical and health company that provides health information and the provision of health promotion and prevention services. |  | Series A | Jul 29, 2020 |  |

10 of 12 investments shown.

## Co-investors
- [Aphelion Capital](https://shizune.co/investors/profile/aphelion-capital) — VC Fund, 4 deals together
- [RiverVest](https://shizune.co/investors/profile/rivervest) — VC Fund, 4 deals together
- [Alpha Wave Ventures](https://shizune.co/investors/profile/alpha-wave-ventures) — VC Fund, 3 deals together
- [AXA Investment Managers](https://shizune.co/investors/profile/axa-investment-managers) — VC Fund, 3 deals together
- [Features Capital](https://shizune.co/investors/profile/features-capital) — VC Fund, 3 deals together
- [Senvest Management](https://shizune.co/investors/profile/rima-management) — VC Fund, 3 deals together

## Similar investors

### Similar industry
- [Warner Music Group](https://shizune.co/investors/profile/warner-music-group) — VC Fund
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Goodwater Capital](https://shizune.co/investors/profile/goodwater-capital) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Mitsubishi UFJ Capital](https://shizune.co/investors/profile/mitsubishi-ufj-capital) — VC Fund
- [SMBC Venture Capital](https://shizune.co/investors/profile/smbc-venture-capital) — VC Fund
- [Mizuho Capital](https://shizune.co/investors/profile/mizuho-capital) — VC Fund

## Featured in investor lists
- [Music Investors in Japan](https://shizune.co/investors/music-investors-japan)
- [Music VC Funds in Japan](https://shizune.co/investors/music-vc-funds-japan)
- [Biotechnology VC Funds in Japan](https://shizune.co/investors/biotechnology-vc-funds-japan)
- [Biotech VC Funds in Japan](https://shizune.co/investors/biotech-vc-funds-japan)

## FAQ

### What does Taisho Pharmaceutical Holdings invest in?

Taisho Pharmaceutical Holdings invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series C stage. Most of the 12 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Taisho Pharmaceutical Holdings's check size?

Taisho Pharmaceutical Holdings typically joins rounds of $2.1M–$12M at Series A and $2.3M–$100M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Taisho Pharmaceutical Holdings participates in.

### How do I contact Taisho Pharmaceutical Holdings?

Public channels for Taisho Pharmaceutical Holdings include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Taisho Pharmaceutical Holdings?

The team at Taisho Pharmaceutical Holdings includes Akira Uehara (Chairman, President, and CEO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co